The 8 analysts offering 12-month price forecasts for BridgeBio Pharma Inc have a median target of 23.50, with a high estimate of 32.00 and a low estimate of 17.00. The median estimate represents a +102.59% increase from the last price of 11.60.
The current consensus among 8 polled investment analysts is to Buy stock in BridgeBio Pharma Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.91
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.